(Q22241379)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20085502%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

review article

1 reference

title

Community acquired bacterial pneumonia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20085502%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20085502%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Demosthenes Bouros

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20085502%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Stavros Anevlavis

1

Stavros

Anevlavis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20085502%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

1 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20085502%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20085502%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20085502%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20085502%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

361-374

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20085502%20AND%20SRC:MED&resulttype=core&format=json

A prediction rule to identify low-risk patients with community-acquired pneumonia

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517/14656560903508770

Community-acquired pneumonia: the U.S. perspective

20 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Increasing hospital admissions for pneumonia, England

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

The cost of treating community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Development and validation of a clinical prediction rule for severe community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Pneumonia: update on diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Adrenal function in patients with community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

2004 update of BTS pneumonia guidelines: what's new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

A prospective study of the diagnostic utility of sputum Gram stain in pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Development of real-time multiplex nucleic acid sequence-based amplification for detection of Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella spp. in respiratory specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Detection of 11 common viral and bacterial pathogens causing community-acquired pneumonia or sepsis in asymptomatic patients by using a multiplex reverse transcription-PCR assay with manual (enzyme hybridization) or automated (electronic microarray)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Evaluation of different nucleic acid amplification techniques for the detection of M. pneumoniae, C. pneumoniae and Legionella spp. in respiratory specimens from patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Rapid diagnosis of pneumococcal pneumonia among HIV-infected adults with urine antigen detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Severe Staphylococcus aureus Infections Caused by Clonally Related Community-Acquired Methicillin-Susceptible and Methicillin-Resistant Isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Methicillin-resistant Staphylococcus aureus disease in three communities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Invasive methicillin-resistant Staphylococcus aureus infections in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

FDA evaluation of antimicrobials: subgroup analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

A worldwide perspective of atypical pathogens in community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Drug-resistant Streptococcus pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Predicting antimicrobial resistance in invasive pneumococcal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Drug-resistance in Streptococcus pneumoniae isolates among Spanish middle aged and older adults with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Hydrocortisone therapy for patients with septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Combination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal Bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Quality of care, process, and outcomes in elderly patients with pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Public reporting of antibiotic timing in patients with pneumonia: lessons from a flawed performance measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Delayed administration of antibiotics and mortality in patients with community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Evidence-based emergency medicine/critically appraised topic. Evidence behind the 4-hour rule for initiation of antibiotic therapy in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Antibiotic timing and errors in diagnosing pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Nosocomial pneumonia. A multivariate analysis of risk and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Nonresolving or slowly resolving pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Factors impacting on length of stay and mortality of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Free and Total Cortisol Levels as Predictors of Severity and Outcome in Community-acquired Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Utility of Fiberoptic Bronchoscopy in Nonresolving Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Detection of Streptococcus pneumoniae Antigen by a Rapid Immunochromatographic Assay in Urine Samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Guidelines for the Treatment of Community-acquired Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

Causes and Factors Associated With Early Failure in Hospitalized Patients With Community-Acquired Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Transtracheal aspiration in pulmonary infection

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

C-reactive protein is an independent predictor of severity in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Diagnosis of Legionella infection

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Measuring acceptable treatment failure rates for community-acquired pneumonia: potential for reducing duration of treatment and antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Guideline tyranny: primum non nocere

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Düsseldorf area

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Identifying barriers to the rapid administration of appropriate antibiotics in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Detection of Legionella pneumophila antigen in urine samples by the BinaxNOW immunochromatographic assay and comparison with both Binax Legionella Urinary Enzyme Immunoassay (EIA) and Biotest Legionella Urin Antigen EIA

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Evaluation of the Binax and Biotest urinary antigen kits for detection of Legionnaires' disease due to multiple serogroups and species of Legionella.

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Markers of treatment failure in hospitalised community acquired pneumonia

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Impact of initial antibiotic choice on mortality from pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

C-reactive protein. A clinical marker in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Plasma d-dimer levels correlate with outcomes in patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Etiological Diagnosis of Bacterial Pneumonia by Gram Stain and Quantitative Culture of Expectorates: Leukocytes or Alveolar Macrophages as Indicators of Sample Representativity

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

Transtracheal Aspiration in the Evaluation of Patients with Pneumonia

1 reference

https://api.crossref.org/works/10.1517%2F14656560903508770

7 January 2021

10.1517/14656560903508770

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

1347360

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20085502%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1347360

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

2 references

1347360